David Pogue is a six-time Emmy winner for his stories on "CBS Sunday Morning," where he's been a correspondent since 2002. Pogue hosts the CBS News podcast "Unsung Science." He's also a New York Times ...

This project provides common data structures and algorithms with clean, expressive, and reusable abstractions — bringing a modern programming experience to C. It includes implementations of widely ...

A hot potato: GitHub has announced that starting April 24, the company will begin using interaction data from Copilot Free, Pro, and Pro+ users to train and improve its AI models unless they opt out.

Democratic senator Elizabeth Warren and Republican senator Josh Hawley are urging the US’s central energy information agency to provide better information on how much electricity data centers actually ...

This story is part of a Seattle Times focus on the affordability crisis in the Northwest. We explore the high cost of living and wealth disparities that shape our region; examine policies that impact ...

This call for proposals (CFP) invites eligible nonprofit organizations in the U.S. to apply for a grant to collect, analyze, and use data to address inequities in the physical, economic, and social ...

Starlink says it may also share personal data with partners to help it "develop AI-enabled tools that improve your customer experience.” Joe Supan is a senior writer for CNET covering home technology, ...

A monthly overview of things you need to know as an architect or aspiring architect. Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with ...

Driven by the artificial intelligence frenzy, Microsoft is internally projecting that water use at its data centers will more than double by 2030 from 2020, including in places that face shortages.

Use the following suggestions to fix the “There is not enough free memory to run this program” error on your Windows computer. The next step is to troubleshoot ...

Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related treatment discontinuation Placebo-adjusted mean weight ...